Wingspan Advisors to Launch WSA Century Fund and Host Alpha Summit to Select Fund Leadership

New York, USA, Jan. 08, 2026 (GLOBE NEWSWIRE) — Wingspan Advisors (WSA), a global investment firm, has announced plans to establish the “WSA Century Investment Fund,” a fund targeting a capital raise of $10 billion. The fund will focus on asset classes across multiple global markets, with particular attention to sectors undergoing structural transformation, such […]

Toobit Launches USDC Trial Funds for Risk-Free Futures Trading

Toobit Launches USDC Trial Funds for Risk-Free Futures Trading GlobeNewswire January 08, 2026 GEORGE TOWN, Cayman Islands, Jan. 08, 2026 (GLOBE NEWSWIRE) — Toobit, the award-winning global cryptocurrency exchange, today announces the launch of its USDC Trial Funds. This new initiative lowers the barrier to entry for futures trading, allowing traders to experience USDC-margined perpetual

Wingspan Advisors to Launch WSA Century Fund and Host Alpha Summit to Select Fund Leadership

Wingspan Advisors to Launch WSA Century Fund and Host Alpha Summit to Select Fund Leadership GlobeNewswire January 08, 2026 New York, USA, Jan. 08, 2026 (GLOBE NEWSWIRE) — Wingspan Advisors (WSA), a global investment firm, has announced plans to establish the “WSA Century Investment Fund,” a fund targeting a capital raise of $10 billion. The

Ontario Details Major Niagara Investment in Exclusive Interview on My Generation, with Host Sam Miele

ST. CATHARINES, Ontario, Jan. 08, 2026 (GLOBE NEWSWIRE) — The Ontario government is advancing a major infrastructure investment to reposition Niagara as a world-class, multi-day tourism destination, according to details outlined in an Exclusive Interview with Host Sam Miele, on the national television program My Generation – airing on The News Forum Thursday January 8th

Fortuna reports progress on its share buyback program

(TSX:FVI),(NYSE:FSM), VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) — Fortuna Mining Corp. (NYSE: FSM | TSX: FVI) is pleased to report that, from Tuesday, December 23, 2025, through Wednesday, January 7, 2026, the Company repurchased an aggregate of 1,700,000 common shares on the open market of the New York Stock Exchange under its normal

New Crypto Mutuum Finance (MUTM) Nears Roadmap Major Milestone Following Halborn Security Review

DUBAI, United Arab Emirates, Jan. 08, 2026 (GLOBE NEWSWIRE) — Mutuum Finance (MUTM), a new crypto project developing a decentralized lending and borrowing protocol, has shared updates tied to its product roadmap after reporting the completion of an external security review. The project stated that Halborn Security completed an independent audit of its V1 lending

Otolaryngologist Evan Sarti, D.O., to Join ENT & Allergy Associates at New, State-of-the-Art Morristown Location in February 2026

Tarrytown, New York, Jan. 08, 2026 (GLOBE NEWSWIRE) — ENT & Allergy Associates, the nation's largest ENT, allergy, and audiology practice, is pleased to announce that Evan Sarti, D.O., a board-certified otolaryngologist and facial plastic surgeon, will join the practice on February 1, 2026 at its new, state-of-the-art clinical location in Morristown, New Jersey. Dr.

ADI Foundation Partners with M-Pesa to Bring 60+ Million Mobile Money Platform Users Onchain

ABU DHABI, United Arab Emirates, Jan. 08, 2026 (GLOBE NEWSWIRE) — The ADI Foundation has partnered with M-Pesa Africa to extend blockchain infrastructure to the platform's 60+ million monthly users. The partnership outlines a framework for deploying ADI Chain across eight African countries where M-Pesa currently operates. The partnership will connect M-Pesa's user base across

Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in Malignant Pleural Mesothelioma (MPM) and Epithelioid Hemangioendothelioma (EHE)

(Helsinki:ORNBV), ORION CORPORATION PRESS RELEASE 8 JANUARY 2026 at 12.00 EET Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in Malignant Pleural Mesothelioma (MPM) and Epithelioid Hemangioendothelioma (EHE) Orion Corporation (Orion Pharma) announces initiation of a Phase 2 trial evaluating ODM-212, a potential best-in-class, oral pan-TEAD inhibitor, as a monotherapy in

Agomab Announces Positive Phase 1 Interim Results with AGMB-447 in Healthy Participants and Initiation of Idiopathic Pulmonary Fibrosis Cohort

— Interim data from Phase 1 with single and multiple ascending doses show no safety signals and a generally favorable tolerability profile of AGMB-447 in healthy participants — — Pharmacokinetic profile in healthy participants shows low systemic exposure of AGMB-447, with high exposure to the lung — — Robust dose-dependent target engagement of ALK5 observed

Scroll to Top